Delivery Order SPE2DB20D3101-SPE2DB25FRQM4
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count supply) with a ceiling value of $51,539.65. This is a firm fixed-price delivery order with an ultimate completion date of July 21, 2025, and represents a competitively awarded contract with no set-aside designation. The work will be performed in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate headquarters...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (180-count units) with a ceiling value of $11,462.52. This firm fixed-price delivery order, with an ultimate completion date of July 21, 2025, represents a competitively awarded contract with no set-aside designation. The work will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania, the company's...
- The Defense Logistics Agency awarded a $3,689.75 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Entresto 24 mg-26 mg tablets (60-count supply) on July 18, 2025, with an ultimate completion date of July 21, 2025. This non-competitive delivery order was placed against AmerisourceBergen's substantial Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The order will be fulfilled at...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 49 mg-51 mg tablets (60-count units) under a firm fixed-price arrangement. The contract, valued at $5,940.34, carries an ultimate completion date of July 21, 2025, and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. This award was competitively procured with no set-aside designation. AmerisourceBergen Drug Corp, a...
- The Defense Logistics Agency awarded a $27,998.28 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 24 mg-26 mg tablets (60-count packages). This is a firm fixed-price, competitively awarded contract with no set-aside designation and an ultimate completion date of July 21, 2025. The contract is being performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a $4,198.26 delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 97 mg-103 mg tablets (180-count units). This is a firm fixed-price, non-set-aside contract with an ultimate completion date of July 21, 2025, with performance taking place at the vendor's corporate office in Conshohocken, Pennsylvania. Entresto is a combination medication used primarily for heart failure treatment, reflecting the critical pharmaceutical...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of Entresto 97 mg-103 mg tablets. The fixed-price delivery order has a ceiling value of $3,492.72 and an ultimate completion date of May 5, 2025. The contract is not set aside and is part of Amerisourcebergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00, which provides a comprehensive...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor, for the supply of 4,566,043,920 tablets of the drug Entresto (49 mg-51 mg). The order has a ceiling value of $2,714.88 and a completion date of October 8, 2024. The contract is a firm fixed-price delivery order, and there is no set-aside designation. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the supply of Entresto 49 mg-51 mg tablets. The contract has a ceiling value of $27,289.22 and is a firm fixed-price, non-set-aside contract with an ultimate completion date of April 22, 2025. AmerisourceBergen Drug Corp holds a substantial Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00, which serves as...
- This is a firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,628.33, is for the delivery of the prescription medication Entresto 24 mg-26 mg tablets. The order has an ultimate completion date of April 24, 2025. AmerisourceBergen Drug Corp is the prime contractor, and the contract is not set-aside. The company holds a larger Indefinite Delivery Contract (IDC) with the DLA...
- SPE2DB20D3101Indefinite Delivery Contract
- SPE2DB20D3101-SPE2DB25FRQM4Delivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 18, 2025, for the supply of Entresto 97 mg-103 mg tablets (60-count units) with a ceiling value of $2,242.17. This is a firm fixed-price, non-set-aside delivery order with an ultimate completion date of July 21, 2025, to be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The award represents a continuation of the company's role as a critical pharmaceutical vendor to federal military and healthcare systems. This delivery order is issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (designated SPE2DX), which is valued at $999,999,999.00 and extends through December 2026. This prime contract vehicle serves as a comprehensive global pharmaceutical support mechanism enabling AmerisourceBergen to supply a broad range of pharmaceuticals and medical supplies to military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. The current delivery order for Entresto, a cardiovascular medication, exemplifies the company's ongoing support of specialized pharmaceutical needs across the federal healthcare system through competitive federal procurement processes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.2k | 7/18/25 |